ACIU Fundamental Analysis - AC IMMUNE SA

Q: Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ACIU.

Q: How profitable is AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a profitability rating of 1 / 10.

Q: How financially healthy is AC IMMUNE SA?

The financial health rating of AC IMMUNE SA (ACIU) is 2 / 10.

Fundamental Rating

Taking everything into account, ACIU scores 2 out of 10 in our fundamental rating. ACIU was compared to 534 industry peers in the Biotechnology industry. ACIU has a bad profitability rating. Also its financial health evaluation is rather negative. ACIU is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ACIU had negative earnings in the past year.

ACIU had a negative operating cash flow in the past year.

In the past 5 years ACIU always reported negative net income.

In the past 5 years ACIU reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of ACIU (-26.55%) is better than 71.35% of its industry peers.

ACIU's Return On Equity of -67.58% is in line compared to the rest of the industry. ACIU outperforms 57.68% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.55%
ROE	-67.58%
ROIC	N/A

ROA(3y)-29.93%

ROA(5y)-28.73%

ROE(3y)-40.33%

ROE(5y)-36.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ACIU has more shares outstanding

The number of shares outstanding for ACIU has been increased compared to 5 years ago.

Compared to 1 year ago, ACIU has a worse debt to assets ratio.

2.2 Solvency

ACIU has an Altman-Z score of -2.34. This is a bad value and indicates that ACIU is not financially healthy and even has some risk of bankruptcy.

ACIU has a Altman-Z score (-2.34) which is comparable to the rest of the industry.

ACIU has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.

ACIU has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: ACIU underperforms 60.67% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	-2.34

ROIC/WACCN/A

WACC4.92%

2.3 Liquidity

A Current Ratio of 1.33 indicates that ACIU should not have too much problems paying its short term obligations.

ACIU has a worse Current ratio (1.33) than 83.52% of its industry peers.

ACIU has a Quick Ratio of 1.33. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of ACIU (1.33) is worse than 82.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.33
Quick Ratio	1.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ACIU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.31%, which is quite impressive.

ACIU shows a strong growth in Revenue. In the last year, the Revenue has grown by 86.71%.

Measured over the past years, ACIU shows a very negative growth in Revenue. The Revenue has been decreasing by -24.39% on average per year.

EPS 1Y (TTM)20.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.7%

Revenue 1Y (TTM)86.71%

Revenue growth 3YN/A

Revenue growth 5Y-24.39%

Sales Q2Q%90.1%

3.2 Future

The Earnings Per Share is expected to grow by 37.54% on average over the next years. This is a very strong growth

ACIU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.41% yearly.

EPS Next Y-49.91%

EPS Next 2Y10.95%

EPS Next 3Y30.58%

EPS Next 5Y37.54%

Revenue Next Year-85.17%

Revenue Next 2Y29.05%

Revenue Next 3Y55.37%

Revenue Next 5Y55.41%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACIU. In the last year negative earnings were reported.

Also next year ACIU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACIU's earnings are expected to grow with 30.58% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.95%

EPS Next 3Y30.58%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ACIU does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AC IMMUNE SA

NASDAQ:ACIU (10/24/2025, 8:07:48 PM)

After market: 3.12 -0.13 (-4%)

3.25

+0.44 (+15.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-05 2025-08-05/bmo

Earnings (Next)11-14 2025-11-14

Inst Owners24.76%

Inst Owner Change0.77%

Ins Owners3.4%

Ins Owner ChangeN/A

Market Cap326.33M

Revenue(TTM)28.92M

Net Income(TTM)-50512000

Analysts86.67

Price Target9.18 (182.46%)

Short Float %2.53%

Short Ratio10.43

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-4.43%

Min EPS beat(2)-18%

Max EPS beat(2)9.14%

EPS beat(4)3

Avg EPS beat(4)33.12%

Min EPS beat(4)-18%

Max EPS beat(4)125.04%

EPS beat(8)4

Avg EPS beat(8)-101.58%

EPS beat(12)8

Avg EPS beat(12)-63%

EPS beat(16)10

Avg EPS beat(16)-68.87%

Revenue beat(2)1

Avg Revenue beat(2)82.49%

Min Revenue beat(2)-35.35%

Max Revenue beat(2)200.32%

Revenue beat(4)3

Avg Revenue beat(4)449.62%

Min Revenue beat(4)-35.35%

Max Revenue beat(4)1583.29%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-3.57%

EPS NQ rev (1m)0%

EPS NQ rev (3m)3.37%

EPS NY rev (1m)0%

EPS NY rev (3m)0.41%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)159.6%

Revenue NY rev (1m)0%

Revenue NY rev (3m)12.08%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	9
P/FCF	N/A
P/OCF	N/A
P/B	3.48
P/tB	10.7
EV/EBITDA	N/A

EPS(TTM)-0.64

EYN/A

EPS(NY)-0.5

Fwd EYN/A

FCF(TTM)-0.54

FCFYN/A

OCF(TTM)-0.53

OCFYN/A

SpS0.36

BVpS0.93

TBVpS0.3

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.55%
ROE	-67.58%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-29.93%

ROA(5y)-28.73%

ROE(3y)-40.33%

ROE(5y)-36.24%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	43.35%
Cap/Sales	3.44%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.33
Quick Ratio	1.33
Altman-Z	-2.34

F-Score4

WACC4.92%

ROIC/WACCN/A

Cap/Depr(3y)38.45%

Cap/Depr(5y)62.34%

Cap/Sales(3y)13.11%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)20.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.7%

EPS Next Y-49.91%

EPS Next 2Y10.95%

EPS Next 3Y30.58%

EPS Next 5Y37.54%

Revenue 1Y (TTM)86.71%

Revenue growth 3YN/A

Revenue growth 5Y-24.39%

Sales Q2Q%90.1%

Revenue Next Year-85.17%

Revenue Next 2Y29.05%

Revenue Next 3Y55.37%

Revenue Next 5Y55.41%

EBIT growth 1Y16.54%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year130.67%

EBIT Next 3Y-16.92%

EBIT Next 5Y-10.94%

FCF growth 1Y30.09%

FCF growth 3YN/A

FCF growth 5Y4.12%

OCF growth 1Y31.11%

OCF growth 3YN/A

OCF growth 5Y3.58%

AC IMMUNE SA / ACIU FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ACIU.

What is the valuation status for ACIU stock?

ChartMill assigns a valuation rating of 1 / 10 to AC IMMUNE SA (ACIU). This can be considered as Overvalued.

How profitable is AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a profitability rating of 1 / 10.

How financially healthy is AC IMMUNE SA?

The financial health rating of AC IMMUNE SA (ACIU) is 2 / 10.

Can you provide the expected EPS growth for ACIU stock?

The Earnings per Share (EPS) of AC IMMUNE SA (ACIU) is expected to decline by -49.91% in the next year.

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AC IMMUNE SA / ACIU FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

What is the valuation status for ACIU stock?

How profitable is AC IMMUNE SA (ACIU) stock?

How financially healthy is AC IMMUNE SA?

Can you provide the expected EPS growth for ACIU stock?